Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis

BACKGROUND: Novel coronavirus (SARS-CoV-2) has infected over 17 million. Novel therapies are urgently needed. Janus-kinase (JAK) inhibitors and Type I interferons have emerged as potential antiviral candidates for COVID-19 patients for their proven efficacy against diseases with excessive cytokine r...

Descripción completa

Detalles Bibliográficos
Autores principales: Walz, Lucas, Cohen, Avi J., Rebaza, Andre P., Vanchieri, James, Slade, Martin D., Dela Cruz, Charles S., Sharma, Lokesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430630/
https://www.ncbi.nlm.nih.gov/pubmed/32817985
http://dx.doi.org/10.1101/2020.08.10.20172189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430630/
https://www.ncbi.nlm.nih.gov/pubmed/32817985
http://dx.doi.org/10.1101/2020.08.10.20172189

Ejemplares similares